Store brand<unk>  cough syrup Cough suppression The primary use of<unk>  is as a cough suppressant, for the temporary relief of cough caused by minor throat and bronchial irritation (such as commonly accompanies the flu and common cold), as well as those resulting from inhaled particle irritants. Neuropsychiatric disorders In 2010, the FDA approved the combination drug<unk> /quinidine for the treatment of pseudobulbar affect (uncontrollable laughing/crying).<unk>  is the actual therapeutic agent in the combination; quinidine merely serves to inhibit the enzymatic degradation of<unk>  and thereby increase its circulating concentrations via inhibition of<unk> . In 2013, a randomized clinical trial found that<unk>  may reduce the overall discomfort and duration of withdrawal symptoms associated with opioid use disorder. When combined with clonidine,<unk>  reduced the overall time needed for withdrawal symptoms to peak by 24 hours while reducing severity of symptoms compared to clonidine alone. The combination medicine<unk> /bupropion is in clinical trials by Axsome Therapeutics for major depressive disorder, with fast track designation granted by the FDA in 2017. The combination showed positive results in phase 2 and phase 3 clinical trials.
Dextromethorphan
Nalorphine
Pethidine
Dextrorphan
Aceclidine
Betamethadol
Fentanyl
Procaine